Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:NSPX OTCMKTS:OREXQ OTCMKTS:PPCB OTCMKTS:SKVI OTCMKTS:STLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNSPXInspyr Therapeutics$0.00$0.00▼$0.07$1.47M-17.3313.19 million shs29.64 million shsOREXQOrexigen Therapeutics$0.01+35.9%$0.01$0.00▼$0.16$100K4.9880,439 shs60,300 shsPPCBPropanc Biopharma$3.44-29.9%$4.30$1.25▼$145.46$65K2.521,806 shs6,000 shsSKVISkinvisible$0.20$0.21$0.16▼$0.85$1.08M1.7692 shs3,800 shsSTLTSpotlight Innovation$0.00$0.00▼$0.04N/AN/AN/A100 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNSPXInspyr Therapeutics0.00%0.00%0.00%0.00%0.00%OREXQOrexigen Therapeutics0.00%0.00%0.00%0.00%0.00%PPCBPropanc Biopharma-18.21%-25.64%-38.66%-55.39%+613,350.00%SKVISkinvisible0.00%-9.09%+13.44%-33.33%-71.01%STLTSpotlight Innovation0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNSPXInspyr TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOREXQOrexigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APPCBPropanc BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ASKVISkinvisibleN/AN/AN/AN/AN/AN/AN/AN/ASTLTSpotlight InnovationN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNSPXInspyr Therapeutics 0.00N/AN/AN/AOREXQOrexigen Therapeutics 0.00N/AN/AN/APPCBPropanc Biopharma 0.00N/AN/AN/ASKVISkinvisible 0.00N/AN/AN/ASTLTSpotlight Innovation 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNSPXInspyr TherapeuticsN/AN/AN/AN/A($0.07) per shareN/AOREXQOrexigen Therapeutics$33.71M0.00N/AN/AN/A∞PPCBPropanc BiopharmaN/AN/AN/AN/A($493.34) per shareN/ASKVISkinvisible$20K54.00N/AN/A($1.86) per share-0.11STLTSpotlight InnovationN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNSPXInspyr Therapeutics-$6.30MN/A0.00N/AN/AN/AN/A-1,354.49%N/AOREXQOrexigen Therapeutics-$24.52MN/A0.00∞N/AN/AN/AN/AN/APPCBPropanc Biopharma-$1.82MN/A0.00∞N/AN/A-3,652.66%-971.09%N/ASKVISkinvisible-$570K-$0.10N/A∞N/A-2,780.00%N/A-359.02%N/ASTLTSpotlight InnovationN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest STLT, PPCB, SKVI, OREXQ, and NSPX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q3 2025PPCBPropanc BiopharmaN/A-$12.50N/A-$12.50N/AN/A5/14/2025Q1 2025SKVISkinvisibleN/A-$0.05N/A-$0.05N/A$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNSPXInspyr TherapeuticsN/AN/AN/AN/AN/AOREXQOrexigen TherapeuticsN/AN/AN/AN/AN/APPCBPropanc BiopharmaN/AN/AN/AN/AN/ASKVISkinvisibleN/AN/AN/AN/AN/ASTLTSpotlight InnovationN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNSPXInspyr TherapeuticsN/A0.090.09OREXQOrexigen TherapeuticsN/AN/AN/APPCBPropanc Biopharma0.012.242.24SKVISkinvisibleN/A0.010.01STLTSpotlight InnovationN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNSPXInspyr Therapeutics0.02%OREXQOrexigen TherapeuticsN/APPCBPropanc BiopharmaN/ASKVISkinvisibleN/ASTLTSpotlight InnovationN/AInsider OwnershipCompanyInsider OwnershipNSPXInspyr Therapeutics0.02%OREXQOrexigen Therapeutics13.30%PPCBPropanc Biopharma0.10%SKVISkinvisible53.00%STLTSpotlight InnovationN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNSPXInspyr Therapeutics1543.15 millionN/ANot OptionableOREXQOrexigen Therapeutics13218.89 millionN/ANot OptionablePPCBPropanc Biopharma119,00019,000Not OptionableSKVISkinvisible25.40 million2.54 millionNot OptionableSTLTSpotlight Innovation4N/AN/ANot OptionableSTLT, PPCB, SKVI, OREXQ, and NSPX HeadlinesRecent News About These CompaniesKDE recognizes Dawson Springs school as a Spotlight SchoolJuly 16 at 3:08 AM | tristatehomepage.comT11 Spotlight Schools recognized by Kentucky Department of EducationJuly 16 at 3:08 AM | kentuckytoday.comKData Spotlight: Measuring trade war exposure, news sentiment & moreJuly 16 at 3:08 AM | bloomberg.comHawaiʻi State Archives Celebrates Local Luthiers with Builder's Spotlight Featuring Molokaʻi's Eric DeVineJuly 16 at 3:08 AM | hoodline.comH2025 Military Support Spotlight: A week of surprises for local nonprofits on 13News NowJuly 16 at 3:08 AM | msn.comGlen Park Vineyards awarded ‘Spotlight on Business’ by Tioga County Chamber of CommerceJuly 16 at 3:08 AM | binghamtonhomepage.comBPokemon GO: Feebas Spotlight Hour Guide (How To Get Shiny Feebas)July 16 at 3:08 AM | msn.comSpotlight Now: Scientists warn federal funding cuts pose danger to HawaiiJuly 15 at 10:06 PM | msn.comSpotlight Now: Doug Simons, Institute for AstronomyJuly 15 at 10:06 PM | hawaiinewsnow.comHSpotlight Now: Scientists warn federal funding cuts pose danger to Hawaii | Full EpisodeJuly 15 at 10:06 PM | hawaiinewsnow.comHUK Actors Union Equity Enters High Court For Landmark Legal Action Against Spotlight, While A Campaign Over Agents’ Commission Kicks OffJuly 14 at 7:44 AM | yahoo.comThe Silver Screen Spotlight: “Superman” and more!July 12, 2025 | weau.comWSpotlight TV: Emily Zubi Talks Dance with Vera & Vladimir Kosarev of Fred Astaire StudiosJuly 12, 2025 | msn.comSophie Cunningham’s Sizzling Outfit Steals the Spotlight at Fever-Dream GameJuly 12, 2025 | msn.com2000s Pop Legend Drops Jaws With Performance After Disappearing From SpotlightJuly 12, 2025 | aol.comAWINC Match Spotlight: Hangman Adam Page Vs. Kenny Omega, AEW Full Gear 2021July 12, 2025 | msn.comSpotlight on the News: Inside the Detroit mayoral race; Craig & BarlowJuly 12, 2025 | wxyz.comWLewis Hamilton and Justin Bieber’s Bond Steals Spotlight as F1 Star Hypes ‘SWAG’ AlbumJuly 12, 2025 | msn.comIndie App Spotlight: ‘Timescape’ is a big-picture calendar for year-round planningJuly 12, 2025 | 9to5mac.com9Angel Reese Reacts After Chicago Sky Teammate Takes the Spotlight on SaturdayJuly 12, 2025 | sports.yahoo.comMedia Sentiment Over TimeSTLT, PPCB, SKVI, OREXQ, and NSPX Company DescriptionsInspyr Therapeutics OTCMKTS:NSPXInspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.Orexigen Therapeutics OTCMKTS:OREXQ$0.0053 +0.00 (+35.90%) As of 05/31/2019Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Propanc Biopharma OTCMKTS:PPCB$3.44 -1.47 (-29.90%) As of 12:56 PM EasternPropanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.Skinvisible OTCMKTS:SKVI$0.20 0.00 (0.00%) As of 07/15/2025 03:37 PM EasternSkinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.Spotlight Innovation OTCMKTS:STLTSpotlight Innovation Inc., a pharmaceutical company, acquires and develops proprietary therapies to address unmet medical needs with an emphasis on rare, emerging, and neglected diseases. It identifies in-licensing opportunities and manages product development through partnerships with universities, medical schools, contract research organizations, and contract manufacturing organizations, as well as pursues product commercialization opportunities, including out-licensing and strategic partnerships. The company is developing Crotoxin, which is in Phase I clinical study for the treatment of cancer. It also develops various compounds for the treatment of viral infections, including Zika virus infection; and products derived from cobra venom to treat chronic pain. Spotlight Innovation Inc. has a license agreement with Indiana University Research and Technology Corporation to commercialize STL-182, an orally-available small molecule that might have therapeutic potential for treating spinal muscular atrophy. The company is based in Urbandale, Iowa. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
